Tweets by @TuftsCEVR


Blog

By CEA Registry Team on 1/18/2017 12:56 PM
This week we highlighted findings from recently published cost-effectiveness studies

PCSK9 inhibitors to reduce cardiovascular risk found to not add value to U.S. health system and is not profitable for private payers: The current price of PCSK9 inhibitors must be reduced by more than 70% in order to be considered a cost-effective drug to fight cardiovascular disease (1)...

SMDM Conference

-

ISPOR's 19th Annual European meeting starts on Sunday, 10/29 in Vienna, Austria.  Here is a list of presentations and discussions by our CEVR investigators:

 

Poster Presentation
Do first-in-class drugs offer larger incremental health gains than next-in-class drugs?
Monday, 10/31 3:45-5:45pm
James Chambers, PhD, MPharm

 

Issue Panel

Emerging US Value Frameworks: Are there lessons from -or for- Europe?
Tuesday, 11/1 1:45-2:45pm
Peter Neumann, ScD

2nd Panel on Cost-Effectiveness for Health and Medicine

-

The 2nd Panel on Cost-Effectiveness for Health and Medicine will host a one-day conference highlighting their findings and recommendations. The conference will be held December 7th in Washington, DC. Click Here for registration information.

-

The agenda for the 2nd Panel on Cost-Effectiveness in Health and Medicine's conference is available

here

.

Interview with MedicalResearch.com

-

MedicalResearch.com interviewed Paige Lin, PhD to discuss her recent paper, "Medicare Expenditures of Individuals with Alzheimer's Disease and Related Dementias or Mild Cognitive Impairment Prior to and Following Diagnosis", published online in JAGS. To read the full interview, click here.

CEA Registry Update

-

CEA Registry update: The database now contains 5,000 studies and over 13,000 standardized cost-effectiveness ratios.